Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand
Biotricity (OTCQB: BTCY) has secured significant financing to strengthen its financial position and reach profitability without requiring future funding. The company completed an $811,000 capital raise through promissory notes, matched with a $635,000 term loan. The lender also provided interest relief by capitalizing $945,000 in existing debt.
This capital enabled Biotricity to place its largest manufacturing order to date, preparing for anticipated 2025 sales. The company's AI workflow engine has improved operational capacity by 50%, with an additional 15% improvement expected. Their next-generation AI cloud system is projected to reduce COGS across their SaaS business by 5% post-FDA clearance.
Biotricity (OTCQB: BTCY) ha ottenuto un finanziamento significativo per rafforzare la sua posizione finanziaria e raggiungere la redditività senza necessitare di futuri finanziamenti. L'azienda ha completato un raccolta di capitali di $811.000 tramite note di prestito, abbinata a un prestito a termine di $635.000. Il prestatore ha inoltre fornito un sollievo sugli interessi capitalizzando $945.000 di debito esistente.
Questo capitale ha consentito a Biotricity di effettuare il suo più grande ordine di produzione fino ad oggi, preparandosi per le vendite previste per il 2025. Il motore di workflow AI dell'azienda ha migliorato la capacità operativa del 50%, con un ulteriore 15% di miglioramento atteso. Si prevede che il loro sistema cloud AI di nuova generazione riduca i COGS nella loro attività SaaS del 5% dopo l'approvazione da parte della FDA.
Biotricity (OTCQB: BTCY) ha conseguido un financiamiento significativo para fortalecer su posición financiera y alcanzar la rentabilidad sin necesidad de financiamiento futuro. La compañía completó una recaudación de capital de $811,000 a través de notas promisorias, acompañada de un préstamo a plazo de $635,000. El prestamista también proporcionó alivio de intereses capitalizando $945,000 en deuda existente.
Este capital permitió a Biotricity realizar su mayor pedido de fabricación hasta la fecha, preparándose para las ventas anticipadas de 2025. El motor de flujo de trabajo de IA de la compañía ha mejorado la capacidad operativa en un 50%, con una mejora adicional del 15% esperada. Se proyecta que su sistema de nube de IA de próxima generación reducirá los COGS en su negocio SaaS en un 5% después de la autorización de la FDA.
Biotricity (OTCQB: BTCY)는 재무 상태를 강화하고 향후 자금 조달 없이 수익성을 달성하기 위한 주요 자금을 확보했습니다. 회사는 약속 어음을 통해 $811,000의 자본 조달을 완료하고, $635,000의 장기 대출을 추가했습니다. 대출자는 또한 기존 부채 중 $945,000을 자본화하여 이자 완화를 제공했습니다.
이 자본은 Biotricity가 지금까지 최대 제조 주문을 할 수 있게 하여, 2025년 예상 매출을 준비하는 데 도움이 되었습니다. 회사의 AI 워크플로 엔진은 운영 능력을 50% 향상시켰으며, 추가로 15%의 향상이 예상됩니다. 차세대 AI 클라우드 시스템은 FDA 승인이 후 SaaS 사업의 COGS를 5% 줄일 것으로 예상됩니다.
Biotricity (OTCQB: BTCY) a obtenu un financement important pour renforcer sa position financière et atteindre la rentabilité sans avoir besoin de financement futur. L'entreprise a complété une levée de fonds de 811 000 $ par le biais de billets à ordre, complétée par un prêt à terme de 635 000 $. Le prêteur a également accordé un allégement des intérêts en capitalisant 945 000 $ de dettes existantes.
Ce capital a permis à Biotricity de passer sa plus grande commande de fabrication à ce jour, se préparant pour les ventes anticipées de 2025. Le moteur de flux de travail IA de l'entreprise a amélioré la capacité opérationnelle de 50%, avec une amélioration supplémentaire de 15% attendue. Leur système cloud IA de nouvelle génération devrait réduire les COGS de leur activité SaaS de 5% après l'approbation de la FDA.
Biotricity (OTCQB: BTCY) hat eine wichtige Finanzierung gesichert, um seine finanzielle Position zu stärken und die Rentabilität ohne zukünftige Finanzierung zu erreichen. Das Unternehmen hat eine Kapitalerhöhung von 811.000 $ durch Schuldscheine abgeschlossen, zusätzlich zu einem Terminkredit von 635.000 $. Der Kreditgeber hat zudem Zinsentlastungen gewährt, indem er 945.000 $ bestehender Schulden kapitalisiert hat.
Dieses Kapital ermöglichte es Biotricity, seine größte Fertigungsbestellung bis heute zu platzieren, um sich auf die erwarteten Verkäufe im Jahr 2025 vorzubereiten. Die KI-Workflow-Engine des Unternehmens hat die Betriebskapazität um 50% gesteigert, wobei eine zusätzliche Verbesserung um 15% erwartet wird. Das nächste KI-Cloud-System der nächsten Generation wird voraussichtlich die COGS in ihrem SaaS-Geschäft nach der FDA-Zulassung um 5% senken.
- Achieved positive Free Cash Flow, a key profitability metric
- Secured $1.446M in new capital ($811K notes + $635K term loan)
- Obtained $945K interest relief through debt capitalization
- AI workflow improved operational capacity by 50%, with additional 15% expected
- Next-gen AI cloud to reduce COGS by 5% post-FDA clearance
- Largest manufacturing order in company history completed
- Increased debt load through new promissory notes and term loan
- Still operating at a loss, with profitability projected for next calendar year
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without any need for future financing.
Dr. Waqaas Al-Siddiq, Biotricity's Founder & CEO, explains: "While continuing on our mission to produce transformative healthcare technologies, we have demonstrated a strong commitment to growth and operational efficiency through innovation, automation and financial discipline, driving revenue and margins on our path to profitability. We also recently announced the significant achievement of positive Free Cash Flow, one of the key metrics towards profitability is Free Cash Flow. In so doing, we received an added vote of confidence from our investors and our largest term lender."
As disclosed within the financial filing of our most recent quarter, the Company added
Al-Siddiq added: "This capital support has allowed the Company to invest in its largest manufacturing order to date, which will allow it to fulfill anticipated sales orders in calendar 2025. This support and the added revenue that will flow from selling the additional inventory and the connected SaaS-based technology sales that those will generate, provides the Company with enough capital to augment its positive Free Cash Flows and achieve its goal of full profitability within the next calendar year. Stated differently, Biotricity has all the inventory and cash resources to achieve profitability without any need for future financing.
"The most exciting part of our story is that we have achieved economies of scale and efficiencies so that as revenues grow, our expenses will grow at a much lower pace. Our proprietary AI workflow engine has already improved our operational capacity by
We expect further operational improvements as we continue to enhance and improve our proprietary AI systems. Our next generation AI cloud will improve COGS across our entire SaaS business by
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Non-GAAP Measures
Free Cash Flow is a non-generally accepted accounting principle ("non-GAAP") measure that represents the cash that the Company generated from its operations after deducting cash used on operating expenses and any capital asset spending. Unlike other accounting measures such as earnings or net income, this measure of profitability excludes non-cash expenses, but includes spending on any capital assets, as well as changes in working capital on the Company's Balance Sheet. Free Cash Flow therefore represents the cash that the Company has generated that is available to repay creditors and pay interest or dividends to lenders and investors.
We provide non-GAAP financial information to enhance the understanding of Biotricity's GAAP financial information; it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. The non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/biotricity-produces-largest-inventory-in-its-history-to-meet-accelerated-demand-302339594.html
SOURCE Biotricity
FAQ
What financing did Biotricity (BTCY) secure in December 2024?
How much has Biotricity's (BTCY) AI workflow engine improved operational capacity?
What cost reduction is expected from Biotricity's (BTCY) next-generation AI cloud?
When does Biotricity (BTCY) expect to achieve full profitability?
Will Biotricity (BTCY) need additional financing to reach profitability?
